Trial Profile

First-in-Human Clinical Study of AGS-499 for Amyotrophic lateral sclerosis

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 27 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jun 2022 According to Neuromagen Pharma media release, the company announced today the establishment of a Scientific Advisory Board and the appointment of Prof. Gal Ifergane, Head of the Neurology Department at Soroka Medical Center as its first membe; Newly formed Scientific Advisory Board will support and advise the company towards submission of in IND and this First-in-Human Clinical Study of AGS-499 for ALS.
13 May 2022 New trial record
21 Mar 2022 According to Neuromagen Pharma media release, the company plans to submit an IND for this first in human trial of AGS-499 by 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com